Literature DB >> 15459752

Neuroprotective effects and intracellular signaling pathways of erythropoietin in a rat model of multiple sclerosis.

M B Sättler1, D Merkler, K Maier, C Stadelmann, H Ehrenreich, M Bähr, R Diem.   

Abstract

In multiple sclerosis (MS), long-term disability is primarily caused by axonal and neuronal damage. We demonstrated in a previous study that neuronal apoptosis occurs early during experimental autoimmune encephalomyelitis, a common animal model of MS. In the present study, we show that, in rats suffering from myelin oligodendrocyte glycoprotein (MOG)-induced optic neuritis, systemic application of erythropoietin (Epo) significantly increased survival and function of retinal ganglion cells (RGCs), the neurons that form the axons of the optic nerve. We identified three independent intracellular signaling pathways involved in Epo-induced neuroprotection in vivo: Protein levels of phospho-Akt, phospho-MAPK 1 and 2, and Bcl-2 were increased under Epo application. Using a combined treatment of Epo together with a selective inhibitor of phosphatidylinositol 3-kinase (PI3-K) prevented upregulation of phospho-Akt and consecutive RGC rescue. We conclude that in MOG-EAE the PI3-K/Akt pathway has an important influence on RGC survival under systemic treatment with Epo.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15459752     DOI: 10.1038/sj.cdd.4401504

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  63 in total

1.  Recombinant Human Erythropoietin: Novel Strategies for Neuroprotective/Neuro-regenerative Treatment of Multiple Sclerosis.

Authors:  Claudia Bartels; Kira Späte; Henning Krampe; Hannelore Ehrenreich
Journal:  Ther Adv Neurol Disord       Date:  2008-11       Impact factor: 6.570

Review 2.  [Programmed cell death in the retina. Molecular mechanisms and therapeutic strategies].

Authors:  P Kermer; M Bähr
Journal:  Ophthalmologe       Date:  2005-07       Impact factor: 1.059

Review 3.  Animal models of multiple sclerosis for the development and validation of novel therapies - potential and limitations.

Authors:  Eilhard Mix; Hans Meyer-Rienecker; Uwe K Zettl
Journal:  J Neurol       Date:  2008-12       Impact factor: 4.849

4.  Cognitive deficit associated with cholinergic and nerve growth factor down-regulation in experimental allergic encephalomyelitis in rats.

Authors:  Giulia D'Intino; Michela Paradisi; Mercedes Fernandez; Alessandro Giuliani; Luigi Aloe; Luciana Giardino; Laura Calzà
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-14       Impact factor: 11.205

5.  [New aspects in the therapy of multiple sclerosis and optic neuritis].

Authors:  W Lagrèze; R Diem
Journal:  Ophthalmologe       Date:  2014-08       Impact factor: 1.059

6.  The Differential Effects of Erythropoietin Exposure to Oxidative Stress on Microglia and Astrocytes in vitro.

Authors:  Praneeti Pathipati; Donna M Ferriero
Journal:  Dev Neurosci       Date:  2017-05-17       Impact factor: 2.984

7.  Allelic variation in the Tyk2 and EGF genes as potential genetic determinants of CNS repair.

Authors:  Allan J Bieber; Kanitta Suwansrinon; Jason Kerkvliet; Weidong Zhang; Larry R Pease; Moses Rodriguez
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-22       Impact factor: 11.205

8.  [Erythropoietin protects retinal ganglion cells and visual function after ocular ischemia and optic nerve compression].

Authors:  T Jehle; W Meschede; R Dersch; N Feltgen; M Bach; W A Lagrèze
Journal:  Ophthalmologe       Date:  2010-04       Impact factor: 1.059

9.  Endogenous erythropoietin as part of the cytokine network in the pathogenesis of experimental autoimmune encephalomyelitis.

Authors:  Manuela Mengozzi; Ilaria Cervellini; Paolo Bigini; Sara Martone; Antonella Biondi; Rosetta Pedotti; Barbara Gallo; Sara Barbera; Tiziana Mennini; Mariaserena Boraso; Marina Marinovich; Edwige Petit; Myriam Bernaudin; Roberto Bianchi; Barbara Viviani; Pietro Ghezzi
Journal:  Mol Med       Date:  2008-07-30       Impact factor: 6.354

10.  Erythropoietin: a multimodal neuroprotective agent.

Authors:  Nadiya Byts; Anna-Leena Sirén
Journal:  Exp Transl Stroke Med       Date:  2009-10-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.